Health spending tied to rise in premiums, new study finds
The study, published last week in JAMA, counters concerns that insurers are raising premiums to pad profits.
Health spending tied to rise in premiums, new study finds Read More »
Novartis drags peers down with triple asset stumble
Novartis’ shares fell 13% this week after the report of three separate late-stage asset setbacks. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
Novartis drags peers down with triple asset stumble Read More »
Samsung Biologics inks $262M manufacturing deal with European pharma company
The agreement, which runs through 2033, comes as Samsung Biologics continues to expand its large manufacturing footprint in South Korea.
Samsung Biologics inks $262M manufacturing deal with European pharma company Read More »
Webinar: The Insider’s Guide to Leveraging Podcasts, Webinars and Thought Leadership Programs
Join BioSpace’s Managing Editor, Director of Insights and Vice President of Marketing for an inside look at how PR, communications and marketing teams can successfully leverage webinars, podcasts and integrated content campaigns to elevate executive voices, share industry expertise and engage key biotech and pharma audiences.
Frazier adds $1.1B+ to small and mid-sized biotech fund
Frazier’s life science fund has already benefited several successful biotechs, including Verona Pharma, which was acquired by Merck for $10 billion, and Carmot Therapeutics, which Roche bought for $2.7 billion.
Frazier adds $1.1B+ to small and mid-sized biotech fund Read More »
Disc sets up polycythemia vera challenge but Silence maintains lead
The polycythemia vera field is heating up, with Disc Medicine and Silence Therapeutics each advancing next-generation therapies, playing catch-up to Takeda and Protagonist Therapeutics, who won the FDA’s approval last month for Mimrylo.
Disc sets up polycythemia vera challenge but Silence maintains lead Read More »
Novartis drags peers down with triple asset failure
Novartis’ shares fell 13% this week after the report of three separate late-stage asset failures. The impact went beyond the Swiss drugmaker, dragging peers down across the market.
Novartis drags peers down with triple asset failure Read More »
Mikhail, Davis embody the FDA’s stabilization, Seehafer signals AI revolution is coming
Newly solidified in their roles as the heads of CBER and CDER, Karim Mikahil and Michael Davis have been working for months to right the ship that had begun to capsize under former Commissioner Marty Makary. Meanwhile, Jared Seehafer will become the first-ever deputy commissioner focused on artificial intelligence.
Mikhail, Davis embody the FDA’s stabilization, Seehafer signals AI revolution is coming Read More »
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops
Back-to-back failures of multiple late-phase trials have raised questions about how Novartis has deployed capital in pursuit of drugs to drive growth through the 2030s.
Novartis’ board faces investor scrutiny after M&A misfires and R&D flops Read More »
Takeda’s long-term R&D head announces exit after major pipeline reorganization
A few months after a new CEO stepped up to helm Takeda, the drugmaker will now have to prepare for another leadership change as its long-time R&D head plans his exit.
Takeda’s long-term R&D head announces exit after major pipeline reorganization Read More »